9801653-8 IPO's copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/38, 31/135 — A1

(11) International Publication Number: WO 97/03665

(43) International Publication Date: 6 February 1997 (06.02.97)

(21) International Application Number: PCT/US96/12047

(22) International Filing Date: 18 July 1996 (18.07.96)

(30) Priority Data:
(1) 60/001,373 — 24 July 1995 (24.07.95) — US
(2) 60/006,349 — 8 November 1995 (08.11.95) — US
(3) 9525909.9 — 19 December 1995 (19.12.95) — GB

(60) Parent Applications or Grants
(63) Related by Continuation
US 60/001,373 (CON)
Filed on 24 July 1995 (24.07.95)
US 60/006,349 (CON)
Filed on 8 November 1995 (08.11.95)

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HEILIGENSTEIN, John, H. [US/US]; 1202 West 56th Street, Indianapolis, IN 46228 (US). PLAGUZZA, Bennett, C. [US/US]; 7340 North Grand Avenue, Indianapolis, IN 46250 (US). PAUL, Steven, M. [US/US]; 1145 Laurelwood, Carmel, IN 46032 (US). TOLLEFSON, Gary, D. [US/US]; 9052 Diamond Pointe, Indianapolis, IN 46236 (US).

(74) Agents: JONES, Joseph, A. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

3 PDs
1 Appln.
4 Invs.

(54) Title: TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

(57) Abstract

A group of propanamines, norepinephrine uptake inhibitors, are used to treat attention-deficit/hyperactivity disorder.

